文献速递生殖医学

低卵巢储备女性在8周低剂量hCG预处理前后卵巢刺激期间雄激素和抑制素B水平的变化

Androgen and inhibin B levels during ovarian stimulation before and after 8 weeks of low-dose hCG priming in women with low ovarian reserve.
PubMed 文献 · Hum Reprod · 2023-01-01

本研究为前瞻性配对非盲单中心研究,纳入20例低卵巢储备(AMH<6.29 pmol/l)女性,比较8周每日260 IU重组hCG预处理前后两个IVF/ICSI周期中血清和卵泡液雄激素与抑制素B水平。结果显示预处理后血清抑制素B、DHEAS及卵泡液睾酮水平降低,而获卵数增多,提示hCG预处理可能并非通过增加卵巢内雄激素水平发挥作用。

要点

  • 8周低剂量hCG预处理后,刺激第1天血清抑制素B和DHEAS显著降低。
  • 预处理后刺激第5-6天血清DHEAS和雄烯二酮显著降低,卵泡液睾酮显著降低。
  • 获卵数在预处理周期显著增多,但卵泡液抑制素B和雄烯二酮无差异。

核心结论

  • 8周低剂量hCG预处理后,血清和卵泡液雄激素水平及血清抑制素B水平下降,获卵数增多。
  • 结果对hCG预处理通过增加卵巢内雄激素水平上调FSHR的理论提出质疑。

研究设计与样本

  • 前瞻性、配对、非盲、单中心研究,于2021年1月至2021年7月在三级医疗中心进行。
  • 纳入20例年龄18-40岁、周期长度23-35天、AMH<6.29 pmol/l的女性。
  • 每例患者接受两个相同的IVF/ICSI周期:对照周期(全部囊胚选择性冷冻)和研究周期(新鲜囊胚移植),两周期之间进行8周(两个月经周期)每日260 IU重组hCG预处理。
  • 两个周期均采用固定GnRH拮抗剂方案。
  • 在刺激第1天、刺激第5-6天、触发日、取卵日及取卵后5天采集血样,取卵时收集两侧第一个抽吸卵泡的卵泡液。

主要发现

  • 刺激第1天,预处理后血清抑制素B低于对照周期(P = 0.05)。
  • 刺激第1天,预处理后血清DHEAS显著低于对照周期(P = 0.03)。
  • 刺激第5-6天,预处理后血清DHEAS和雄烯二酮均显著低于对照周期(P = 0.02和P = 0.02)。
  • 研究周期卵泡液睾酮水平显著低于对照周期(P = 0.008),而卵泡液抑制素B和雄烯二酮浓度在两周期之间无差异。
  • 研究周期获卵数显著多于对照周期,且触发日直径≥10-mm卵泡的雌二醇产量在两周期相当。

局限性

  • 样本量小,且研究未随机化。
  • 研究设计无法测量和比较hCG预处理期之前和刚结束后小窦卵泡中的雄激素水平或FSHR表达。
  • 作者指出,改善的周期结局(即更多获卵数)必须在更大规模、最好为随机化的研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does 8 weeks of daily low-dose hCG administration affect androgen or inhibin B levels in serum and/or follicular fluid (FF) during the subsequent IVF/ICSI cycle in women with low ovarian reserve? SUMMARY ANSWER: Androgen levels in serum and FF, and inhibin B levels in serum, decreased following 8 weeks of hCG administration. WHAT IS KNOWN ALREADY: Recently, we showed that 8 weeks of low-dose hCG priming, in between two IVF/ICSI treatments in women with poor ovarian responder (anti-Müllerian hormone (AMH) <6.29 pmol/l), resulted in more follicles of 2-5 mm and less of 6-10-mm diameter at the start of stimulation and more retrieved oocytes at oocyte retrieval. The duration of stimulation and total FSH consumption was increased in the IVF/ICSI cycle after priming. Hypothetically, hCG priming stimulates intraovarian androgen synthesis causing upregulation of FSH receptors (FSHR) on granulosa cells. It was therefore unexpected that antral follicles were smaller and the stimulation time longer after hCG priming. This might indicate a different mechanism of action than previously suggested. STUDY DESIGN, SIZE, DURATION: Blood samples were drawn on stimulation day 1, stimulation days 5-6, trigger day, day of oocyte retrieval, and oocyte retrieval + 5 days in the IVF/ICSI cycles before and after hCG priming (the control and study cycles, respectively). FF was collected from the first aspirated follicle on both sides during oocyte retrieval in both cycles. The study was conducted as a prospective, paired, non-blinded, single-center study conducted between January 2021 and July 2021 at a tertiary care center. The 20 participants underwent two identical IVF/ICSI treatments: a control cycle including elective freezing of all blastocysts and a study cycle with fresh blastocyst transfer. The control and study cycles were separated by 8 weeks (two menstrual cycles) of hCG priming by daily injections of 260 IU recombinant hCG. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women aged 18-40 years with cycle lengths of 23-35 days and AMH <6.29 pmol/l were included. Control and study IVF/ICSI cycles were performed in a fixed GnRH-antagonist protocol. MAIN RESULTS AND THE ROLE OF CHANCE: Inhibin B was lower on stimulation day 1 after hCG priming (P = 0.05). Dehydroepiandrosterone sulfate (DHEAS) was significantly lower on stimulation day 1 (P = 0.03), and DHEAS and androstenedione were significantly lower on stimulation days 5-6 after priming (P = 0.02 and P = 0.02) The testosterone level in FF was significantly lower in the study cycle (P = 0.008), while the concentrations of inhibin B and androstenedione in the FF did not differ between the study and control cycles. A lower serum inhibin B in the study cycle corresponds with the antral follicles being significantly smaller after priming, and this probably led to a longer stimulation time in the study cycle. This contradicts the theory that hCG priming increases the intraovarian androgen level, which in turn causes more FSHR on developing (antral up to preovulatory) follicles. However, based on this study, we cannot rule out that an increased intra-follicular androgen level was present at initiation of the ovarian stimulation, without elevating the androgen level in serum and that an increased androgen level may have rescued some small antral follicles that would have otherwise undergone atresia by the end of the previous menstrual cycle. We retrieved significantly more oocytes in the Study cycle, and the production of estradiol per follicle ≥10-mm diameter on trigger day was comparable in the study and control cycles, suggesting that the rescued follicles were competent in terms of producing oocytes and steroid hormones. LIMITATIONS, REASONS FOR CAUTION: The sample size was small, and the study was not randomized. Our study design did not allow for the measurement and comparison of androgen levels or FSHR expression in small antral follicles before and immediately after the hCG-priming period. WIDER IMPLICATIONS OF THE FINDINGS: The results make us question the mechanism of action behind hCG priming prior to IVF. It is important to design a study with the puncture of small antral follicles before and immediately after priming to investigate the proposed hypothesis. Improved cycle outcomes, i.e. more retrieved oocytes, must be confirmed in a larger, preferably randomized study. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by an unrestricted grant from Gedeon Richter awarded to the institution. A.P. reports personal consulting fees from PregLem SA, Novo Nordisk A/S, Ferring Pharmaceuticals A/S, Gedeon Richter Nordics AB, Cryos International, and Merck A/S outside the submitted work and payment or honoraria for lectures from Gedeon Richter Nordics AB, Ferring Pharmaceuticals A/S, Merck A/S, and Theramex and Organon & Co and payment for participation in an advisory board for Preglem. Grants to the institution have been provided by Gedeon Richter Nordics AB, Ferring Pharmaceuticals A/S, and Merck A/S, and equipment and travel support has been given to the institution by Gedeon Richter Nordics AB. The remaining authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT04643925.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Friis Wang N, Bogstad JW, Petersen MR, et al. Androgen and inhibin B levels during ovarian stimulation before and after 8 weeks of low-dose hCG priming in women with low ovarian reserve. Hum Reprod. 2023. PMID: 37354554. doi:10.1093/humrep/dead134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。